Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Acumen Pharmaceuticals, Inc. Common Stock (ABOS)

Biological Products, (no Disgnostic Substances)

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

427 PARK ST.
CHARLOTTESVILLE, VA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/01/2021

Market Cap

154,104,687

Shares Outstanding

57,910,000

Weighted SO

57,910,461

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

TERN --.--%

XFOR --.--%

DAWN --.--%

HOOK --.--%

AMLX --.--%

INZY --.--%

MREO --.--%

Beta

0.1110

Last Div

0.0000

Range

1.81-6.78

Chg

-0.0100

Avg Vol

444246

Mkt Cap

154104687

Exch

NASDAQ

Country

US

Phone

434 297 1000

DCF Diff

1.8247

DCF

0.7373

Div Yield

0.0000

P/S

531.3955

EV Multiple

-1.5128

P/FV

0.6317

Div Yield %

0.0000

P/E

-2.3758

PEG

0.2970

Payout

0.0000

Current Ratio

17.3694

Quick Ratio

17.3694

Cash Ratio

4.4221

DSO

133.4138

DIO

0.0022

Op Cycle

133.4160

DPO

9148.8988

CCC

-9015.4828

Gross Margin

0.4207

Op Margin

-264.4138

Pretax Margin

-223.6690

Net Margin

-223.6690

Eff Tax Rate

-0.0565

ROA

-0.2245

ROE

-0.2463

ROCE

-0.2803

NI/EBT

1.0000

EBT/EBIT

0.8459

EBIT/Rev

-264.4138

Debt Ratio

0.1021

D/E

0.1209

LT Debt/Cap

0.1075

Total Debt/Cap

0.1079

Int Coverage

53.8862

CF/Debt

-1.8852

Equity Multi

1.1843

Rec Turnover

2.7358

Pay Turnover

0.0399

Inv Turnover

168000.0000

FA Turnover

0.6744

Asset Turnover

0.0010

OCF/Share

-0.9258

FCF/Share

-0.9264

Cash/Share

4.3354

OCF/Sales

-191.8034

FCF/OCF

1.0007

CF Coverage

-1.8852

ST Coverage

-444.9840

CapEx Coverage

-1503.3243

Div&CapEx Cov

-1503.3243

P/BV

0.6317

P/B

0.6317

P/S

531.3955

P/E

-2.3758

P/FCF

-2.7687

P/OCF

-2.7705

P/CF

-2.7705

PEG

0.2970

P/S

531.3955

EV Multiple

-1.5128

P/FV

0.6317

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 04, 16:15 Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Nov 06, 07:30 Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology GlobeNewswire Inc. Oct 27, 09:25 Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

Revenue Product Segmentation